Immunohistochemical detection of EGFR, fibrillin‐2, P‐cadherin and AP2β as biomarkers for rhabdomyosarcoma diagnostics
- 1 June 2009
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 54 (7), 873-879
- https://doi.org/10.1111/j.1365-2559.2009.03303.x
Abstract
AIMS: Subclassification of rhabdomyosarcoma (RMS) has clinical relevance, as the two major subclasses embryonal (ERMS) and alveolar (ARMS) rhabdomyosarcoma differ greatly in terms of aggressiveness and prognosis. However, histological analysis is not always sufficient for an unequivocal subclassification of RMS. Furthermore, clinical presentation of ARMS has been reported to mimic other tumour types, specifically lymphoma. The aim was to determine the role of four biomarkers in the diagnosis of rhabdomyosarcoma. METHODS AND RESULTS: Recently, we identified four potential biomarkers to subclassify RMS with high sensitivity and specificity. These included epidermal growth factor receptor (EGFR) and fibrillin-2 as markers for ERMS, and AP2beta and P-cadherin as markers for translocation-positive ARMS. Here, we further validate the potential of these four markers in a second, independent patient cohort by immunohistochemistry on 80 sections of RMS biopsy specimens as well as a tissue microarray representing 18 different additional tumour types, including seven lymphomas. The combination of EGFR and fibrillin-2 was able to detect ERMS with a specificity of 76% and sensitivity of 90%. The combination of AP2beta and P-cadherin detected ARMS with a specificity of 97% and sensitivity of 90%, data very similar to our previous study. Furthermore, all lymphomas were clearly negative for AP2beta and P-cadherin. CONCLUSIONS: These four biomarkers are suitable for clinical implementation in the future diagnosis of RMSKeywords
This publication has 13 references indexed in Scilit:
- Initial Patient Characteristics Can Predict Pattern and Risk of Relapse in Localized RhabdomyosarcomaJournal of Clinical Oncology, 2008
- Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHROncogene, 2007
- Global gene expression profiling of PAX‐FKHR fusion‐positive alveolar and PAX‐FKHR fusion‐negative embryonal rhabdomyosarcomasThe Journal of Pathology, 2007
- Alveolar rhabdomyosarcoma mimicking lymphoma with bone marrow involvementEuropean Journal of Pediatrics, 2006
- Alveolar Rhabdomyosarcoma Mimicking a Lymphoma at PresentationJournal of Clinical Oncology, 2006
- Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar RhabdomyosarcomasCancer Research, 2006
- Subtype and Prognostic Classification of Rhabdomyosarcoma by ImmunohistochemistryJournal of Clinical Oncology, 2006
- Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcomaLaboratory Investigation, 2006
- Are Myogenin and MyoD1 Expression Specific for Rhabdomyosarcoma?The American Journal of Surgical Pathology, 2001
- Rhabdomyosarcoma presenting as ‘acute leukaemia’Histopathology, 1991